For the year ending 2025-12-31, MTNB had -$3,285K decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 |
|---|---|
| Amortization of bond premium | 0 |
| Impairment charges of goodwill and other intangible assets | 0 |
| Impairment charges of other assets | 0 |
| Income tax benefit | 0 |
| Depreciation and amortization | 32 |
| Net gain on disposal of assets | 37 |
| Loss on operating lease right-of-use assets modification | 241 |
| Prepaid expenses and other current assets | -665 |
| Accounts payable | 220 |
| Accrued expenses and other liabilities | -1,353 |
| Operating lease liabilities | -1,042 |
| Net loss | -10,345 |
| Change in fair value of warrant liability | 3,161 |
| Amortization of operating lease right-of-use assets | 420 |
| Amortization of finance lease right-of-use assets | 4 |
| Stock-based compensation expense | 1,023 |
| Net cash used in operating activities | -7,011 |
| Purchases of marketable debt securities | 0 |
| Proceeds from sales of marketable debt securities | 0 |
| Proceeds from sale of assets | 335 |
| Net cash provided by investing activities | 335 |
| Net proceeds from public offerings of common stock and warrants | 0 |
| Gross proceeds from private placement of preferred stock and common stock warrants | 3,300 |
| Transaction costs paid pursuant to private placement | 29 |
| Net proceeds from exercise of warrants | 129 |
| Payments of capital lease liability principal | 9 |
| Net cash provided by financing activities | 3,391 |
| Net (decrease)/increase in cash, cash equivalents and restricted cash | -3,285 |
| Net (decrease)/increase in cash, cash equivalents and restricted cash | -3,285 |
| Cash, cash equivalents and restricted cash at beginning of period | 7,534 |
| Cash, cash equivalents and restricted cash at end of period | 4,249 |
Matinas BioPharma Holdings, Inc. (MTNB)
Matinas BioPharma Holdings, Inc. (MTNB)